Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica

Introduction During the maintenance dialysis as well the pre-dialysis period anemia represents one of the most frequent and debilitating diseases associated with chronic kidney disease (CKD). If anemia is untreated, the quality of life is reduced and survival is shortened. Epoetin and darbepoetin alfa are Erythropoietin Receptor Agonists (ERAs) indicated for the treatment of anemia in patients with CKD.